GlassScriptPhysician profile
Heather Melton
NPI 1669807830
$6,891.49
in general payments reported to CMS, 2019-2025
38 companies · $1,708 in 2025
The $1,708 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,264 · 2022: $1,172 · 2023: $1,358 · 2024: $1,391 · 2025: $1,708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,456.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $969.41 | 2021-2025 | Rexulti |
| Novo Nordisk INC | $932.06 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $889.79 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $570.33 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $482.18 | 2021-2025 | Repatha, Otezla, Evenity |
| Corcept Therapeutics | $309.15 | 2021-2025 | Korlym |
| Axsome Therapeutics, INC. | $231.95 | 2024-2025 | Auvelity |
| Pfizer INC. | $206.66 | 2021-2025 | |
| Lundbeck LLC | $197.81 | 2022-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $194.33 | 2021-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $182.39 | 2021-2023 | Trintellix |
| Lilly USA, LLC | $180.39 | 2021-2025 | Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $174.93 | 2022-2025 | |
| Glaxosmithkline, LLC. | $173.18 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $155.82 | 2023-2025 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Melton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.